Positive on Mphasis, Infosys; Recommend Alembic Pharma: Abhimanyu Sofat, 英雄联盟竞猜观看最新版�
Research In The News

Positive on Mphasis, Infosys; Recommend Alembic Pharma: Abhimanyu Sofat, 英雄联盟竞猜观看最新版�

"We have been recommending Alembic Pharma where we are seeing 17 percent growth and free cash flow improvement of Rs 50 crore going up to Rs 200 crore next year and in two years, going to around Rs 400 crore," says Abhimanyu Sofat, Head of Research at 英雄联盟竞猜观看最新版 Securities.�
18 Jul, 2019, 08:48 IST | Kolkata, India
Positive on Mphasis, Infosys; Recommend Alembic Pharma: Abhimanyu Sofat, 英雄联盟竞猜观看最新版�

As a house, we believe that Infosys has a better risk reward as compared to TCS. However, it is the mid-cap companies like Mphasis where the upside is likely to be better since multiples are at a significant discount to these companies and the earnings growth is expected to be pretty good.?In the pharma space, despite the correction, we are not that bullish on Sun Pharma as of now.?We would prefer some of the mid-cap stocks.?We have been recommending Alembic Pharma where we are seeing 17 per cent growth and free cash flow improvement of Rs 50 crore going up to Rs 200 crore next year and in two years, going to around Rs 400 crore.?It is more of a bottoms up kind of an approach within the pharmaceutical sector and as of now, Sun continues to be negative.?

lol英雄联盟在线登录网站 战雄电竞(兰州)下注季节 esg电竞(江苏)平台在线2.8.4 英雄联盟竞猜下载入口v4.4 IOS版 星火电竞公告比赛 电竞体育(武汉)观看全球网址